A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity
about
Inhibition of pathological brain angiogenesis through systemic delivery of AAV vector expressing soluble FLT1.Delivery of sFIT-1 engineered MSCs in combination with a continuous low-dose doxorubicin treatment prevents growth of liver cancer.Particulate matter-mediated release of long pentraxin 3 (PTX3) and vascular endothelial growth factor (VEGF) in vitro: Limited importance of endotoxin and organic content.Utilizing Zebrafish to Identify Anti-(Lymph)Angiogenic Compounds for Cancer Treatment: Promise and Future Challenges.Monitoring antiangiogenesis of bevacizumab in zebrafish
P2860
A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A novel engineered VEGF blocke ...... and robust anti-tumor activity
@ast
A novel engineered VEGF blocke ...... and robust anti-tumor activity
@en
type
label
A novel engineered VEGF blocke ...... and robust anti-tumor activity
@ast
A novel engineered VEGF blocke ...... and robust anti-tumor activity
@en
prefLabel
A novel engineered VEGF blocke ...... and robust anti-tumor activity
@ast
A novel engineered VEGF blocke ...... and robust anti-tumor activity
@en
P2093
P2860
P1433
P1476
A novel engineered VEGF blocke ...... and robust anti-tumor activity
@en
P2093
Charles C Chu
Hongzhi Tan
Huifeng Jia
Ruliang Zhang
Sumei Jiang
Wenzhi Tian
P2860
P2888
P356
10.1186/S12885-015-1140-1
P407
P577
2015-03-25T00:00:00Z
P5875
P6179
1009217201